From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
All | China | Japan | South Korea | Taiwan | p-value | |
---|---|---|---|---|---|---|
Primary Role, % | ||||||
Clinicians | 60.0 | 15.0 | 15.0 | 15.0 | 15.0 | 0.196 |
Hepatologist | 18.8 | 2.5 | 5.0 | 7.5 | 3.8 | |
Oncologist | 21.3 | 10.0 | 2.5 | 1.3 | 7.5 | |
Radiologist | 3.8 | 1.3 | 1.3 | 1.3 | 0.0 | |
Surgeon | 12.5 | 0.0 | 8.3 | 4.2 | 0.0 | |
Other | 3.8 | 0.4 | 1.1 | 1.1 | 1.1 | |
Policy makers | 25.0 | 6.3 | 6.3 | 6.3 | 6.3 | 0.167 |
Governmental | 18.8 | 5.0 | 6.3 | 5.0 | 2.5 | |
Non-Governmental | 6.3 | 1.3 | 0.0 | 1.3 | 3.8 | |
Advocates | 15.0 | 3.8 | 3.8 | 3.8 | 3.8 | 0.518 |
Disease advocacy | 5.0 | 0.0 | 1.3 | 1.3 | 2.5 | |
Media/Spokesperson | 3.8 | 1.3 | 1.3 | 0.0 | 1.3 | |
Patient advocacy | 6.3 | 2.5 | 1.3 | 2.5 | 0.0 | |
Area of Involvement, % | 0.002** | |||||
Hepatitis | 26.3 | 5.0 | 11.3 | 3.8 | 6.3 | |
HCC | 57.5 | 17.5 | 13.7 | 16.3 | 10.0 | |
Metastatic liver cancer | 10.0 | 2.5 | 0.0 | 0.0 | 7.5 | |
Transplantation | 6.3 | 0.0 | 0.0 | 5.0 | 1.3 | |
Level of Involvement, % | 0.029* | |||||
International | 15.0 | 3.8 | 3.8 | 5.0 | 2.5 | |
Local/municipality | 6.3 | 5.0 | 0.0 | 1.3 | 0.0 | |
National | 56.3 | 13.7 | 11.3 | 17.5 | 13.7 | |
Regional/provincial | 22.5 | 2.5 | 10.0 | 1.3 | 8.8 |